{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:12:41Z","timestamp":1794507161702,"version":"4.9.1"},"reference-count":300,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41574-023-00898-1","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:01:57Z","timestamp":1697439717000},"page":"27-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":268,"title":["Inter-organ crosstalk during development and progression of type 2 diabetes mellitus"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1540-0310","authenticated-orcid":false,"given":"Georgia","family":"Xourafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis","family":"Korbmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8200-6382","authenticated-orcid":false,"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"898_CR1","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed, N. A. et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes \u2013 2023. Diabetes Care 46, S19\u2013S40 (2022).","journal-title":"Diabetes Care"},{"key":"898_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-016-0374-9","volume":"15","author":"J Szendroedi","year":"2016","unstructured":"Szendroedi, J. et al. Cohort profile: the German Diabetes Study (GDS). Cardiovasc. Diabetol. 15, 59 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"898_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","volume":"373","author":"AG Tab\u00e1k","year":"2009","unstructured":"Tab\u00e1k, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215\u20132221 (2009).","journal-title":"Lancet"},{"key":"898_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","volume":"576","author":"M Roden","year":"2019","unstructured":"Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51\u201360 (2019). A comprehensive review describing the current understanding of the development of T2DM, specifically addressing the role of lipid mediators.","journal-title":"Nature"},{"key":"898_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.468","volume":"11","author":"X He","year":"2021","unstructured":"He, X., Kuang, G., Wu, Y. & Ou, C. Emerging roles of exosomal miRNAs in diabetes mellitus. Clin. Transl. Med. 11, e468 (2021).","journal-title":"Clin. Transl. Med."},{"key":"898_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41580-021-00354-w","volume":"22","author":"P Agbu","year":"2021","unstructured":"Agbu, P. & Carthew, R. W. MicroRNA-mediated regulation of glucose and lipid metabolism. Nat. Rev. Mol. Cell Biol. 22, 425\u2013438 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"898_CR7","doi-asserted-by":"publisher","first-page":"154892","DOI":"10.1016\/j.metabol.2021.154892","volume":"125","author":"L Mastrototaro","year":"2021","unstructured":"Mastrototaro, L. & Roden, M. Insulin resistance and insulin sensitizing agents. Metabolism 125, 154892 (2021).","journal-title":"Metabolism"},{"key":"898_CR8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cmet.2021.08.006","volume":"33","author":"R Isaac","year":"2021","unstructured":"Isaac, R., Reis, F. C. G., Ying, W. & Olefsky, J. M. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. 33, 1744\u20131762 (2021).","journal-title":"Cell Metab."},{"key":"898_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41580-021-00390-6","volume":"22","author":"DE James","year":"2021","unstructured":"James, D. E., St\u00f6ckli, J. & Birnbaum, M. J. The aetiology and molecular landscape of insulin resistance. Nat. Rev. Mol. Cell Biol. 22, 751\u2013771 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"898_CR10","doi-asserted-by":"publisher","first-page":"101304","DOI":"10.1016\/j.molmet.2021.101304","volume":"52","author":"MF White","year":"2021","unstructured":"White, M. F. & Kahn, C. R. Insulin action at a molecular level \u2013 100 years of progress. Mol. Metab. 52, 101304 (2021). A review focusing on the molecular biology of the insulin signalling cascade.","journal-title":"Mol. Metab."},{"key":"898_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00125-018-4777-x","volume":"62","author":"PE Scherer","year":"2019","unstructured":"Scherer, P. E. The many secret lives of adipocytes: implications for diabetes. Diabetologia 62, 223\u2013232 (2019).","journal-title":"Diabetologia"},{"key":"898_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41577-019-0213-9","volume":"19","author":"MY Donath","year":"2019","unstructured":"Donath, M. Y., Dinarello, C. A. & Mandrup-Poulsen, T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat. Rev. Immunol. 19, 734\u2013746 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"898_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-pharmtox-052220-010446","volume":"62","author":"Z Mirzadeh","year":"2022","unstructured":"Mirzadeh, Z., Faber, C. L. & Schwartz, M. W. Central nervous system control of glucose homeostasis: a therapeutic target for type 2 diabetes? Annu. Rev. Pharmacol. Toxicol. 62, 55\u201384 (2022).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"898_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"Hepatology"},{"key":"898_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s42255-019-0145-5","volume":"1","author":"C Priest","year":"2019","unstructured":"Priest, C. & Tontonoz, P. Inter-organ cross-talk in metabolic syndrome. Nat. Metab. 1, 1177\u20131188 (2019).","journal-title":"Nat. Metab."},{"key":"898_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s00125-021-05625-x","volume":"65","author":"C Herder","year":"2022","unstructured":"Herder, C. & Roden, M. A novel diabetes typology: towards precision diabetology from pathogenesis to treatment. Diabetologia 65, 770\u20131781 (2022).","journal-title":"Diabetologia"},{"key":"898_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2337\/dc21-1705","volume":"45","author":"J Morze","year":"2022","unstructured":"Morze, J. et al. Metabolomics and type 2 diabetes risk: an updated systematic review and meta-analysis of prospective cohort studies. Diabetes Care 45, 1013\u20131024 (2022). This meta-analysis illustrates the association of numerous lipids and amino acids with increased risk of insulin resistance and T2DM.","journal-title":"Diabetes Care"},{"key":"898_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121434","volume":"3","author":"ML Steinhauser","year":"2018","unstructured":"Steinhauser, M. L. et al. The circulating metabolome of human starvation. JCI Insight 3, e121434 (2018).","journal-title":"JCI Insight"},{"key":"898_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00125-023-05879-7","volume":"66","author":"S Yuan","year":"2023","unstructured":"Yuan, S., Merino, J. & Larsson, S. C. Causal factors underlying diabetes risk informed by Mendelian randomisation analysis: evidence, opportunities and challenges. Diabetologia 66, 800\u2013812 (2023). This review discusses the findings of Mendelian randomization studies with regard to causality in the development of T2DM.","journal-title":"Diabetologia"},{"key":"898_CR20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00015.2017","volume":"98","author":"S Gancheva","year":"2018","unstructured":"Gancheva, S., Jelenik, T., \u00c1lvarez-Hern\u00e1ndez, E. & Roden, M. Interorgan metabolic crosstalk in human insulin resistance. Physiol. Rev. 98, 1371\u20131415 (2018). This review addresses the mechanisms by which metabolites contribute to inter-organ crosstalk in the context of insulin resistance.","journal-title":"Physiol. Rev."},{"key":"898_CR21","doi-asserted-by":"publisher","first-page":"e8996","DOI":"10.1073\/pnas.1804379115","volume":"115","author":"BM Gassaway","year":"2018","unstructured":"Gassaway, B. M. et al. PKC\u03b5 contributes to lipid-induced insulin resistance through cross talk with p70S6K and through previously unknown regulators of insulin signaling. Proc. Natl Acad. Sci. USA 115, e8996\u2013e9005 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"898_CR22","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1172\/JCI118742","volume":"97","author":"M Roden","year":"1996","unstructured":"Roden, M. et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97, 2859\u20132865 (1996).","journal-title":"J. Clin. Invest."},{"key":"898_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s001250051579","volume":"44","author":"H Stingl","year":"2001","unstructured":"Stingl, H. et al. Lipid-dependent control of hepatic glycogen stores in healthy humans. Diabetologia 44, 48\u201354 (2001).","journal-title":"Diabetologia"},{"key":"898_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1172\/JCI118160","volume":"96","author":"G Boden","year":"1995","unstructured":"Boden, G. & Chen, X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J. Clin. Invest. 96, 1261\u20131268 (1995).","journal-title":"J. Clin. Invest."},{"key":"898_CR25","doi-asserted-by":"publisher","first-page":"9597","DOI":"10.1073\/pnas.1409229111","volume":"111","author":"J Szendroedi","year":"2014","unstructured":"Szendroedi, J. et al. Role of diacylglycerol activation of PKC\u03b8 in lipid-induced muscle insulin resistance in humans. Proc. Natl Acad. Sci. USA 111, 9597\u20139602 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"898_CR26","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.2337\/db12-1179","volume":"62","author":"B Nowotny","year":"2013","unstructured":"Nowotny, B. et al. Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans. Diabetes 62, 2240\u20132248 (2013).","journal-title":"Diabetes"},{"key":"898_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00125-021-05596-z","volume":"65","author":"T Sarabhai","year":"2022","unstructured":"Sarabhai, T. et al. Dietary palmitate and oleate differently modulate insulin sensitivity in human skeletal muscle. Diabetologia 65, 301\u2013314 (2022). This clinical study shows how differently saturated lipids activate specific cellular pathways to induce insulin resistance in healthy humans.","journal-title":"Diabetologia"},{"key":"898_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.cmet.2020.08.001","volume":"32","author":"K Lyu","year":"2020","unstructured":"Lyu, K. et al. A membrane-bound diacylglycerol species induces PKC\u03f5-mediated hepatic insulin resistance. Cell Metab. 32, 654\u2013664.e5 (2020). An interesting study showing the deleterious role of sn-1,2-diacylglycerol in insulin signalling pathways, in humans indirectly by its high levels in the circulation of people with insulin resistance, and in animals directly by showing its mechanism of action.","journal-title":"Cell Metab."},{"key":"898_CR29","volume":"6","author":"K Lyu","year":"2021","unstructured":"Lyu, K. et al. Short-term overnutrition induces white adipose tissue insulin resistance through sn-1,2-diacylglycerol\/PKC\u03b5\/insulin receptor Thr1160 phosphorylation. JCI Insight 6, e139946 (2021).","journal-title":"JCI Insight"},{"key":"898_CR30","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2337\/db16-1147","volume":"66","author":"T Jelenik","year":"2017","unstructured":"Jelenik, T. et al. Mechanisms of insulin resistance in primary and secondary nonalcoholic fatty liver. Diabetes 66, 2241\u20132253 (2017).","journal-title":"Diabetes"},{"key":"898_CR31","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.2337\/db18-0449","volume":"67","author":"T Jelenik","year":"2018","unstructured":"Jelenik, T. et al. Insulin resistance and vulnerability to cardiac ischemia. Diabetes 67, 2695\u20132702 (2018).","journal-title":"Diabetes"},{"key":"898_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cmet.2018.09.013","volume":"29","author":"AE Brandon","year":"2019","unstructured":"Brandon, A. E. et al. Protein kinase C epsilon deletion in adipose tissue, but not in liver, improves glucose tolerance. Cell Metab. 29, 183\u2013191.e7 (2019).","journal-title":"Cell Metab."},{"key":"898_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13017","volume":"48","author":"K B\u00f3dis","year":"2018","unstructured":"B\u00f3dis, K. & Roden, M. Energy metabolism of white adipose tissue and insulin resistance in humans. Eur. J. Clin. Invest. 48, e13017 (2018).","journal-title":"Eur. J. Clin. Invest."},{"key":"898_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tem.2017.03.005","volume":"28","author":"J Iqbal","year":"2017","unstructured":"Iqbal, J., Walsh, M. T., Hammad, S. M. & Hussain, M. M. Sphingolipids and lipoproteins in health and metabolic disorders. Trends Endocrinol. Metab. 28, 506\u2013518 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"898_CR35","doi-asserted-by":"publisher","first-page":"684448","DOI":"10.3389\/fendo.2021.684448","volume":"12","author":"M Mah","year":"2021","unstructured":"Mah, M., Febbraio, M. & Turpin-Nolan, S. Circulating ceramides \u2013 are origins important for sphingolipid biomarkers and treatments? Front. Endocrinol. 12, 684448 (2021).","journal-title":"Front. Endocrinol."},{"key":"898_CR36","doi-asserted-by":"publisher","first-page":"100270","DOI":"10.1016\/j.jlr.2022.100270","volume":"63","author":"S Zarini","year":"2022","unstructured":"Zarini, S. et al. Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro. J. Lipid Res. 63, 100270 (2022).","journal-title":"J. Lipid Res."},{"key":"898_CR37","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2337\/dc17-1318","volume":"41","author":"M Apostolopoulou","year":"2018","unstructured":"Apostolopoulou, M. et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care 41, 1235\u20131243 (2018).","journal-title":"Diabetes Care"},{"key":"898_CR38","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","volume":"19","author":"Q Yang","year":"2018","unstructured":"Yang, Q., Vijayakumar, A. & Kahn, B. B. Metabolites as regulators of insulin sensitivity and metabolism. Nat. Rev. Mol. Cell Biol. 19, 654\u2013672 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"898_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.tem.2020.03.004","volume":"31","author":"M Rocha","year":"2020","unstructured":"Rocha, M., Apostolova, N., Diaz-Rua, R., Muntane, J. & Victor, V. M. Mitochondria and T2D: role of autophagy, ER stress, and inflammasome. Trends Endocrinol. Metab. 31, 725\u2013741 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"898_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","volume":"140","author":"GS Hotamisligil","year":"2010","unstructured":"Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900\u2013917 (2010).","journal-title":"Cell"},{"key":"898_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134520","volume":"5","author":"T Sarabhai","year":"2020","unstructured":"Sarabhai, T. et al. Monounsaturated fat rapidly induces hepatic gluconeogenesis and whole-body insulin resistance. JCI Insight 5, e134520 (2020).","journal-title":"JCI Insight"},{"key":"898_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1172\/JCI89444","volume":"127","author":"E Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez, E. et al. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J. Clin. Invest. 127, 695\u2013708 (2017).","journal-title":"J. Clin. Invest."},{"key":"898_CR43","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/metabo12121238","volume":"12","author":"M Misheva","year":"2022","unstructured":"Misheva, M., Johnson, J. & McCullagh, J. Role of oxylipins in the inflammatory-related diseases NAFLD, obesity, and type 2 diabetes. Metabolites 12, 1238 (2022).","journal-title":"Metabolites"},{"key":"898_CR44","doi-asserted-by":"publisher","first-page":"bqaa235","DOI":"10.1210\/endocr\/bqaa235","volume":"162","author":"W Massey","year":"2021","unstructured":"Massey, W. & Brown, J. M. The gut microbial endocrine organ in type 2 diabetes. Endocrinology 162, bqaa235 (2021).","journal-title":"Endocrinology"},{"key":"898_CR45","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41392-023-01439-y","volume":"8","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal. Transduct. Target. Ther. 8, 220 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"898_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.bbrc.2015.03.094","volume":"460","author":"W Ren","year":"2015","unstructured":"Ren, W., Sun, Y. & Du, K. Glut4 palmitoylation at Cys223 plays a critical role in Glut4 membrane trafficking. Biochem. Biophys. Res. Commun. 460, 709\u2013714 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"898_CR47","doi-asserted-by":"publisher","first-page":"101261","DOI":"10.1016\/j.molmet.2021.101261","volume":"52","author":"PJ White","year":"2021","unstructured":"White, P. J. et al. Insulin action, type 2 diabetes, and branched-chain amino acids: a two-way street. Mol. Metab. 52, 101261 (2021). This review article discusses the contribution of amino acids to T2DM pathogenesis.","journal-title":"Mol. Metab."},{"key":"898_CR48","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00125-018-4619-x","volume":"61","author":"P Welsh","year":"2018","unstructured":"Welsh, P. et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia 61, 1581\u20131591 (2018).","journal-title":"Diabetologia"},{"key":"898_CR49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41574-018-0055-8","volume":"14","author":"S Kahl","year":"2018","unstructured":"Kahl, S. & Roden, M. Amino acids \u2013 lifesaver or killer in patients with diabetes? Nat. Rev. Endocrinol. 14, 449\u2013451 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR50","doi-asserted-by":"publisher","first-page":"E1175","DOI":"10.1152\/ajpendo.00630.2012","volume":"304","author":"DE Lackey","year":"2013","unstructured":"Lackey, D. E. et al. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am. J. Physiol. Endocrinol. Metab. 304, E1175\u2013E1187 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"898_CR51","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2337\/diabetes.51.3.599","volume":"51","author":"M Krebs","year":"2002","unstructured":"Krebs, M. et al. Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. Diabetes 51, 599\u2013605 (2002).","journal-title":"Diabetes"},{"key":"898_CR52","doi-asserted-by":"publisher","first-page":"14056","DOI":"10.1073\/pnas.0706517104","volume":"104","author":"F Tremblay","year":"2007","unstructured":"Tremblay, F. et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc. Natl Acad. Sci. USA 104, 14056\u201314061 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"898_CR53","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00125-003-1129-1","volume":"46","author":"M Krebs","year":"2003","unstructured":"Krebs, M. et al. Direct and indirect effects of amino acids on hepatic glucose metabolism in humans. Diabetologia 46, 917\u2013925 (2003).","journal-title":"Diabetologia"},{"key":"898_CR54","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/ajcn\/nqz191","volume":"110","author":"Y Karusheva","year":"2019","unstructured":"Karusheva, Y. et al. Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial. Am. J. Clin. Nutr. 110, 1098\u20131107 (2019).","journal-title":"Am. J. Clin. Nutr."},{"key":"898_CR55","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1172\/JCI74915","volume":"124","author":"T Laeger","year":"2014","unstructured":"Laeger, T. et al. FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913\u20133922 (2014).","journal-title":"J. Clin. Invest."},{"key":"898_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32000-0","volume":"13","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IR\u03b2. Nat. Commun. 13, 4291 (2022).","journal-title":"Nat. Commun."},{"key":"898_CR57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/dom.12155","volume":"15","author":"C Herder","year":"2013","unstructured":"Herder, C., Carstensen, M. & Ouwens, D. M. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes. Metab. 15, 39\u201350 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"898_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","volume":"127","author":"AR Saltiel","year":"2017","unstructured":"Saltiel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest. 127, 1\u20134 (2017).","journal-title":"J. Clin. Invest."},{"key":"898_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1172\/JCI29881","volume":"117","author":"CN Lumeng","year":"2007","unstructured":"Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175\u2013184 (2007).","journal-title":"J. Clin. Invest."},{"key":"898_CR60","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","volume":"10","author":"F Zatterale","year":"2019","unstructured":"Zatterale, F. et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front. Physiol. 10, 1607 (2019).","journal-title":"Front. Physiol."},{"key":"898_CR61","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.cell.2014.05.012","volume":"157","author":"YunS Lee","year":"2014","unstructured":"Lee, YunS. et al. Increased adipocyte O2 consumption triggers HIF-1\u03b1, causing inflammation and insulin resistance in obesity. Cell 157, 1339\u20131352 (2014).","journal-title":"Cell"},{"key":"898_CR62","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","volume":"160","author":"RJ Perry","year":"2015","unstructured":"Perry, R. J. et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745\u2013758 (2015).","journal-title":"Cell"},{"key":"898_CR63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201416","volume":"218","author":"F He","year":"2021","unstructured":"He, F. et al. Mitophagy-mediated adipose inflammation contributes to type 2 diabetes with hepatic insulin resistance. J. Exp. Med. 218, e20201416 (2021).","journal-title":"J. Exp. Med."},{"key":"898_CR64","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0092-8674(88)80008-4","volume":"54","author":"MF White","year":"1988","unstructured":"White, M. F. et al. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 54, 641\u2013649 (1988).","journal-title":"Cell"},{"key":"898_CR65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1172\/JCI88877","volume":"127","author":"K Eguchi","year":"2017","unstructured":"Eguchi, K. & Nagai, R. Islet inflammation in type 2 diabetes and physiology. J. Clin. Invest. 127, 14\u201323 (2017).","journal-title":"J. Clin. Invest."},{"key":"898_CR66","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41574-021-00510-4","volume":"17","author":"J Yong","year":"2021","unstructured":"Yong, J., Johnson, J. D., Arvan, P., Han, J. & Kaufman, R. J. Therapeutic opportunities for pancreatic \u03b2-cell ER stress in diabetes mellitus. Nat. Rev. Endocrinol. 17, 455\u2013467 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","volume":"55","author":"TV Rohm","year":"2022","unstructured":"Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity 55, 31\u201355 (2022).","journal-title":"Immunity"},{"key":"898_CR68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cmet.2018.12.003","volume":"29","author":"W Ying","year":"2019","unstructured":"Ying, W. et al. Expansion of islet-resident macrophages leads to inflammation affecting \u03b2 cell proliferation and function in obesity. Cell Metab. 29, 457\u2013474.e5 (2019).","journal-title":"Cell Metab."},{"key":"898_CR69","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.molmet.2020.101122","volume":"50","author":"K Pafili","year":"2021","unstructured":"Pafili, K. & Roden, M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol. Metab. 50, 101122 (2021).","journal-title":"Mol. Metab."},{"key":"898_CR70","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2337\/db07-1403","volume":"57","author":"PD Cani","year":"2008","unstructured":"Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470\u20131481 (2008).","journal-title":"Diabetes"},{"key":"898_CR71","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3389\/fimmu.2020.01582","volume":"11","author":"G Daryabor","year":"2020","unstructured":"Daryabor, G., Atashzar, M. R., Kabelitz, D., Meri, S. & Kalantar, K. The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front. Immunol. 11, 1582 (2020).","journal-title":"Front. Immunol."},{"key":"898_CR72","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cmet.2020.12.019","volume":"33","author":"W Ying","year":"2021","unstructured":"Ying, W. et al. MiR-690, an exosomal-derived miRNA from M2-polarized macrophages, improves insulin sensitivity in obese mice. Cell Metab. 33, 781\u2013790.e5 (2021).","journal-title":"Cell Metab."},{"key":"898_CR73","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1210\/clinem\/dgz166","volume":"105","author":"Z Semnani-Azad","year":"2020","unstructured":"Semnani-Azad, Z. et al. The macrophage activation marker soluble CD163 is longitudinally associated with insulin sensitivity and \u03b2-cell function. J. Clin. Endocrinol. Metab. 105, e285\u2013e294 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"898_CR74","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.2337\/dc20-1918","volume":"44","author":"Z Semnani-Azad","year":"2021","unstructured":"Semnani-Azad, Z. et al. Adipose tissue insulin resistance is longitudinally associated with adipose tissue dysfunction, circulating lipids, and dysglycemia: the PROMISE cohort. Diabetes Care 44, 1682\u20131691 (2021).","journal-title":"Diabetes Care"},{"key":"898_CR75","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1194\/jlr.R094060","volume":"60","author":"JB Funcke","year":"2019","unstructured":"Funcke, J. B. & Scherer, P. E. Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J. Lipid Res. 60, 1648\u20131684 (2019).","journal-title":"J. Lipid Res."},{"key":"898_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2013.12.012","volume":"156","author":"ED Rosen","year":"2014","unstructured":"Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. Cell 156, 20\u201344 (2014).","journal-title":"Cell"},{"key":"898_CR77","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrn.2018.7","volume":"19","author":"A Caron","year":"2018","unstructured":"Caron, A., Lee, S., Elmquist, J. K. & Gautron, L. Leptin and brain-adipose crosstalks. Nat. Rev. Neurosci. 19, 153\u2013165 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"898_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endrev\/bnaa027","volume":"42","author":"S Pereira","year":"2021","unstructured":"Pereira, S., Cline, D. L., Glavas, M. M., Covey, S. D. & Kieffer, T. J. Tissue-specific effects of leptin on glucose and lipid metabolism. Endocr. Rev. 42, 1\u201328 (2021).","journal-title":"Endocr. Rev."},{"key":"898_CR79","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s42255-019-0041-z","volume":"1","author":"LG Straub","year":"2019","unstructured":"Straub, L. G. & Scherer, P. E. Metabolic messengers: adiponectin. Nat. Metab. 1, 334\u2013339 (2019).","journal-title":"Nat. Metab."},{"key":"898_CR80","first-page":"3","volume":"6","author":"RJ Perry","year":"2018","unstructured":"Perry, R. J. & Shulman, G. I. The role of leptin in maintaining plasma glucose during starvation. Postdoc J. 6, 3\u201319 (2018).","journal-title":"Postdoc J."},{"key":"898_CR81","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cmet.2022.09.020","volume":"34","author":"M Metz","year":"2022","unstructured":"Metz, M. et al. Leptin increases hepatic triglyceride export via a vagal mechanism in humans. Cell Metab. 34, 1719\u20131731.e5 (2022). This study shows how a brain\u2013vagus-nerve\u2013liver crosstalk explains a novel effect of leptin.","journal-title":"Cell Metab."},{"key":"898_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001140","volume":"8","author":"X Wang","year":"2020","unstructured":"Wang, X., Jia, J. & Huang, T. Shared genetic architecture and casual relationship between leptin levels and type 2 diabetes: large-scale cross-trait meta-analysis and Mendelian randomization analysis. BMJ Open. Diabetes Res. Care 8, e001140 (2020).","journal-title":"BMJ Open. Diabetes Res. Care"},{"key":"898_CR83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2009.02.131","volume":"382","author":"M Awazawa","year":"2009","unstructured":"Awazawa, M. et al. Adiponectin suppresses hepatic SREBP1c expression in an adipoR1\/LKB1\/AMPK dependent pathway. Biochem. Biophys. Res. Commun. 382, 51\u201356 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"898_CR84","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nature08991","volume":"464","author":"M Iwabu","year":"2010","unstructured":"Iwabu, M. et al. Adiponectin and AdipoR1 regulate PGC-1\u03b1 and mitochondria by Ca2+ and AMPK\/SIRT1. Nature 464, 1313\u20131319 (2010).","journal-title":"Nature"},{"key":"898_CR85","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.2337\/db13-0128","volume":"62","author":"H Yaghootkar","year":"2013","unstructured":"Yaghootkar, H. et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62, 3589\u20133598 (2013).","journal-title":"Diabetes"},{"key":"898_CR86","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.2337\/db12-0935","volume":"62","author":"H Gao","year":"2013","unstructured":"Gao, H. et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 62, 1338\u20131344 (2013).","journal-title":"Diabetes"},{"key":"898_CR87","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.117.001837","volume":"10","author":"MC Borges","year":"2017","unstructured":"Borges, M. C. et al. Metabolic profiling of adiponectin levels in adults: Mendelian randomization analysis. Circ. Cardiovasc. Genet. 10, e001837 (2017).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"898_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-016-0339-z","volume":"15","author":"L Ortega Moreno","year":"2016","unstructured":"Ortega Moreno, L. et al. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc. Diabetol. 15, 17 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"898_CR89","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.2337\/db21-0131","volume":"70","author":"MB Nielsen","year":"2021","unstructured":"Nielsen, M. B., \u00c7olak, Y., Benn, M. & Nordestgaard, B. G. Low plasma adiponectin in risk of type 2 diabetes: observational analysis and one- and two-sample Mendelian randomization analyses 756,219 individuals. Diabetes 70, 2694\u20132705 (2021). This Mendelian randomization analysis provides evidence for a causal association between low adiponectin levels and higher risk of T2DM.","journal-title":"Diabetes"},{"key":"898_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32\u201342 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"898_CR91","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2337\/db15-0881","volume":"65","author":"C Nowak","year":"2016","unstructured":"Nowak, C. et al. Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes 65, 276\u2013284 (2016).","journal-title":"Diabetes"},{"key":"898_CR92","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1161\/ATVBAHA.116.308320","volume":"36","author":"G Liu","year":"2016","unstructured":"Liu, G. et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study. Arterioscler. Thromb. Vasc. Biol. 36, 2259\u20132267 (2016).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"898_CR93","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad015","author":"KA Brown","year":"2023","unstructured":"Brown, K. A. & Scherer, P. E. Update on adipose tissue and cancer. Endocr Rev. https:\/\/doi.org\/10.1210\/endrev\/bnad015 (2023).","journal-title":"Endocr Rev."},{"key":"898_CR94","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/CIRCRESAHA.122.321295","volume":"131","author":"C Schiborn","year":"2022","unstructured":"Schiborn, C. et al. Retinol and retinol binding protein 4 levels and cardiometabolic disease risk. Circ. Res. 131, 637\u2013649 (2022).","journal-title":"Circ. Res."},{"key":"898_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4485","volume":"5","author":"K Sun","year":"2014","unstructured":"Sun, K. et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat. Commun. 5, 3485 (2014).","journal-title":"Nat. Commun."},{"key":"898_CR96","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00125-016-4094-1","volume":"60","author":"MA Karsdal","year":"2017","unstructured":"Karsdal, M. A. et al. Serum endotrophin identifies optimal responders to PPAR\u03b3 agonists in type 2 diabetes. Diabetologia 60, 50\u201359 (2017).","journal-title":"Diabetologia"},{"key":"898_CR97","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13098-020-00564-w","volume":"12","author":"S Naiemian","year":"2020","unstructured":"Naiemian, S. et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol. Metab. Syndr. 12, 65 (2020).","journal-title":"Diabetol. Metab. Syndr."},{"key":"898_CR98","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cytogfr.2021.05.002","volume":"60","author":"K Shabir","year":"2021","unstructured":"Shabir, K. et al. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: comprehensive review of preclinical and clinical evidence. Cytokine Growth Factor. Rev. 60, 120\u2013132 (2021).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"898_CR99","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere, C. et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 165, 566\u2013579 (2016).","journal-title":"Cell"},{"key":"898_CR100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","volume":"158","author":"JC Lo","year":"2014","unstructured":"Lo, J. C. et al. Adipsin is an adipokine that improves \u03b2 cell function in diabetes. Cell 158, 41\u201353 (2014).","journal-title":"Cell"},{"key":"898_CR101","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/ijms23042222","volume":"23","author":"M Milek","year":"2022","unstructured":"Milek, M. et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int. J. Mol. Sci. 23, 2222 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"898_CR102","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41586-021-04234-3","volume":"601","author":"R Garcia-Martin","year":"2022","unstructured":"Garcia-Martin, R. et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature 601, 446\u2013451 (2022).","journal-title":"Nature"},{"key":"898_CR103","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/oby.22379","volume":"27","author":"YU Bae","year":"2019","unstructured":"Bae, Y. U. et al. Bariatric surgery alters microRNA content of circulating exosomes in patients with obesity. Obesity 27, 264\u2013271 (2019).","journal-title":"Obesity"},{"key":"898_CR104","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1038\/s41366-022-01227-8","volume":"46","author":"YJ Abozaid","year":"2022","unstructured":"Abozaid, Y. J. et al. Plasma circulating microRNAs associated with obesity, body fat distribution, and fat mass: the Rotterdam study. Int. J. Obes. 46, 2137\u20132144 (2022).","journal-title":"Int. J. Obes."},{"key":"898_CR105","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ajcn\/nqac070","volume":"116","author":"Y Heianza","year":"2022","unstructured":"Heianza, Y. et al. Changes in circulating microRNAs-99\/100 and reductions of visceral and ectopic fat depots in response to lifestyle interventions: the CENTRAL trial. Am. J. Clin. Nutr. 116, 165\u2013172 (2022).","journal-title":"Am. J. Clin. Nutr."},{"key":"898_CR106","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature21365","volume":"542","author":"T Thomou","year":"2017","unstructured":"Thomou, T. et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542, 450\u2013455 (2017).","journal-title":"Nature"},{"key":"898_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03693-0","volume":"20","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Mitochondrial transplantation: opportunities and challenges in the treatment of obesity, diabetes, and nonalcoholic fatty liver disease. J. Transl. Med. 20, 483 (2022).","journal-title":"J. Transl. Med."},{"key":"898_CR108","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.cmet.2022.08.010","volume":"34","author":"N Borcherding","year":"2022","unstructured":"Borcherding, N. et al. Dietary lipids inhibit mitochondria transfer to macrophages to divert adipocyte-derived mitochondria into the blood. Cell Metab. 34, 1499\u20131513.e8 (2022). This preclinical study suggests a novel mechanism by which mitochondrial transfer might mediate metabolic adaptation to a dietary stimulus.","journal-title":"Cell Metab."},{"key":"898_CR109","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.cmet.2020.11.008","volume":"33","author":"JR Brestoff","year":"2021","unstructured":"Brestoff, J. R. et al. Intercellular mitochondria transfer to macrophages regulates white adipose tissue homeostasis and is impaired in obesity. Cell Metab. 33, 270\u2013282.e8 (2021).","journal-title":"Cell Metab."},{"key":"898_CR110","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cmet.2021.08.002","volume":"33","author":"C Crewe","year":"2021","unstructured":"Crewe, C. et al. Extracellular vesicle-based interorgan transport of mitochondria from energetically stressed adipocytes. Cell Metab. 33, 1853\u20131868.e11 (2021).","journal-title":"Cell Metab."},{"key":"898_CR111","doi-asserted-by":"publisher","first-page":"140172","DOI":"10.1016\/j.bbapap.2018.11.009","volume":"1867","author":"S Hartwig","year":"2019","unstructured":"Hartwig, S. et al. Exosomal proteins constitute an essential part of the human adipose tissue secretome. Biochim. Biophys. Acta Proteins Proteom. 1867, 140172 (2019).","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"898_CR112","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2337\/dbi21-0020","volume":"71","author":"DE Kahn","year":"2022","unstructured":"Kahn, D. E. & Bergman, B. C. Keeping it local in metabolic disease: adipose tissue paracrine signaling and insulin resistance. Diabetes 71, 599\u2013609 (2022).","journal-title":"Diabetes"},{"key":"898_CR113","doi-asserted-by":"publisher","first-page":"bqac140","DOI":"10.1210\/endocr\/bqac140","volume":"163","author":"D Kahn","year":"2022","unstructured":"Kahn, D. et al. Exploring visceral and subcutaneous adipose tissue secretomes in human obesity: implications for metabolic disease. Endocrinology 163, bqac140 (2022).","journal-title":"Endocrinology"},{"key":"898_CR114","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jhep.2022.08.010","volume":"77","author":"K Pafili","year":"2022","unstructured":"Pafili, K. et al. Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease. J. Hepatol. 77, 1504\u20131514 (2022).","journal-title":"J. Hepatol."},{"key":"898_CR115","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jgg.2021.09.009","volume":"49","author":"S Lu","year":"2022","unstructured":"Lu, S., Wang, Y. & Liu, J. Tumor necrosis factor-\u03b1 signaling in nonalcoholic steatohepatitis and targeted therapies. J. Genet. Genomics 49, 269\u2013278 (2022).","journal-title":"J. Genet. Genomics"},{"key":"898_CR116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41574-020-00431-8","volume":"17","author":"GH Goossens","year":"2021","unstructured":"Goossens, G. H., Jocken, J. W. E. & Blaak, E. E. Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat. Rev. Endocrinol. 17, 47\u201366 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR117","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/obr.12862","volume":"20","author":"RCR Meex","year":"2019","unstructured":"Meex, R. C. R., Blaak, E. E. & van Loon, L. J. C. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes. Rev. 20, 1205\u20131217 (2019).","journal-title":"Obes. Rev."},{"key":"898_CR118","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41574-022-00641-2","volume":"18","author":"LS Chow","year":"2022","unstructured":"Chow, L. S. et al. Exerkines in health, resilience and disease. Nat. Rev. Endocrinol. 18, 273\u2013289 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR119","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-019-4947-5","volume":"62","author":"SK Vasan","year":"2019","unstructured":"Vasan, S. K. et al. The proposed systemic thermogenic metabolites succinate and 12,13-diHOME are inversely associated with adiposity and related metabolic traits: evidence from a large human cross-sectional study. Diabetologia 62, 2079\u20132087 (2019).","journal-title":"Diabetologia"},{"key":"898_CR120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCULATIONAHA.120.049813","volume":"143","author":"KM Pinckard","year":"2021","unstructured":"Pinckard, K. M. et al. A novel endocrine role for the BAT-released lipokine 12,13-diHOME to mediate cardiac function. Circulation 143, 145\u2013159 (2021).","journal-title":"Circulation"},{"key":"898_CR121","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00125-019-4927-9","volume":"62","author":"J Eckel","year":"2019","unstructured":"Eckel, J. Myokines in metabolic homeostasis and diabetes. Diabetologia 62, 1523\u20131528 (2019).","journal-title":"Diabetologia"},{"key":"898_CR122","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/eci.12781","volume":"47","author":"BK Pedersen","year":"2017","unstructured":"Pedersen, B. K. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur. J. Clin. Invest. 47, 600\u2013611 (2017).","journal-title":"Eur. J. Clin. Invest."},{"key":"898_CR123","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00125-019-05045-y","volume":"63","author":"H Ellingsgaard","year":"2020","unstructured":"Ellingsgaard, H. et al. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia 63, 362\u2013373 (2020).","journal-title":"Diabetologia"},{"key":"898_CR124","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cmet.2018.04.008","volume":"27","author":"L Lang Lehrskov","year":"2018","unstructured":"Lang Lehrskov, L. et al. Interleukin-6 delays gastric emptying in humans with direct effects on glycemic. Control. Cell Metab. 27, 1201\u20131211.e3 (2018).","journal-title":"Control. Cell Metab."},{"key":"898_CR125","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/obr.12567","volume":"18","author":"Y Duan","year":"2017","unstructured":"Duan, Y. et al. Interleukin-15 in obesity and metabolic dysfunction: current understanding and future perspectives. Obes. Rev. 18, 1147\u20131158 (2017).","journal-title":"Obes. Rev."},{"key":"898_CR126","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13723","volume":"6","author":"R Sabaratnam","year":"2018","unstructured":"Sabaratnam, R. et al. Intact regulation of muscle expression and circulating levels of myokines in response to exercise in patients with type 2 diabetes. Physiol. Rep. 6, e13723 (2018).","journal-title":"Physiol. Rep."},{"key":"898_CR127","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.3390\/ijms23094636","volume":"23","author":"R Balakrishnan","year":"2022","unstructured":"Balakrishnan, R. & Thurmond, D. C. Mechanisms by which skeletal muscle myokines ameliorate insulin resistance. Int. J. Mol. Sci. 23, 4636 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"898_CR128","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1152\/ajpendo.00353.2017","volume":"314","author":"JP Barlow","year":"2018","unstructured":"Barlow, J. P. & Solomon, T. P. Do skeletal muscle-secreted factors influence the function of pancreatic \u03b2-cells? Am. J. Physiol. Endocrinol. Metab. 314, E297\u2013E307 (2018).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"898_CR129","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2337\/db10-1178","volume":"60","author":"K Bouzakri","year":"2011","unstructured":"Bouzakri, K. et al. Bimodal effect on pancreatic \u03b2-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60, 1111\u20131121 (2011).","journal-title":"Diabetes"},{"key":"898_CR130","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10777","volume":"481","author":"P Bostr\u00f6m","year":"2012","unstructured":"Bostr\u00f6m, P. et al. A PGC1-\u03b1-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463\u2013468 (2012).","journal-title":"Nature"},{"key":"898_CR131","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cmet.2013.12.003","volume":"19","author":"LD Roberts","year":"2014","unstructured":"Roberts, L. D. et al. \u03b2-Aminoisobutyric acid induces browning of white fat and hepatic \u03b2-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 19, 96\u2013108 (2014).","journal-title":"Cell Metab."},{"key":"898_CR132","doi-asserted-by":"publisher","first-page":"100053","DOI":"10.1016\/j.metop.2020.100053","volume":"7","author":"JP Barlow","year":"2020","unstructured":"Barlow, J. P. et al. Beta-aminoisobutyric acid is released by contracting human skeletal muscle and lowers insulin release from INS-1 832\/3 cells by mediating mitochondrial energy metabolism. Metab. Open. 7, 100053 (2020).","journal-title":"Metab. Open."},{"key":"898_CR133","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fendo.2019.00331","volume":"10","author":"M Ramanjaneya","year":"2019","unstructured":"Ramanjaneya, M. et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front. Endocrinol. 10, 331 (2019).","journal-title":"Front. Endocrinol."},{"key":"898_CR134","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158449","volume":"132","author":"B Miller","year":"2022","unstructured":"Miller, B., Kim, S. J., Kumagai, H., Yen, K. & Cohen, P. Mitochondria-derived peptides in aging and healthspan. J. Clin. Invest. 132, e158449 (2022).","journal-title":"J. Clin. Invest."},{"key":"898_CR135","doi-asserted-by":"publisher","first-page":"E723","DOI":"10.1152\/ajpendo.00138.2018","volume":"315","author":"RF D\u2019Souza","year":"2018","unstructured":"D\u2019Souza, R. F. et al. Circulatory exosomal miRNA following intense exercise is unrelated to muscle and plasma miRNA abundances. Am. J. Physiol. Endocrinol. Metab. 315, E723\u2013e733 (2018).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"898_CR136","doi-asserted-by":"publisher","first-page":"eabi9551","DOI":"10.1126\/sciadv.abi9551","volume":"7","author":"M Apostolopoulou","year":"2021","unstructured":"Apostolopoulou, M. et al. Metabolic responsiveness to training depends on insulin sensitivity and protein content of exosomes in insulin-resistant males. Sci. Adv. 7, eabi9551 (2021). This clinical\u2013experimental study shows that physical exercise can affect exosome content and composition, which relates to exercise responsiveness depending on the degree of glucose tolerance in humans.","journal-title":"Sci. Adv."},{"key":"898_CR137","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","volume":"78","author":"B Fromenty","year":"2023","unstructured":"Fromenty, B. & Roden, M. Mitochondrial alterations in fatty liver diseases. J. Hepatol. 78, 415\u2013429 (2023).","journal-title":"J. Hepatol."},{"key":"898_CR138","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-nutr-071715-050656","volume":"36","author":"C Koliaki","year":"2016","unstructured":"Koliaki, C. & Roden, M. Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus. Annu. Rev. Nutr. 36, 337\u2013367 (2016).","journal-title":"Annu. Rev. Nutr."},{"key":"898_CR139","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jhep.2022.03.017","volume":"77","author":"A Beaulant","year":"2022","unstructured":"Beaulant, A. et al. Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis. J. Hepatol. 77, 710\u2013722 (2022). This study introduces the ER\u2013mitochondria interaction as a novel mechanism contributing to the pathogenesis of T2DM.","journal-title":"J. Hepatol."},{"key":"898_CR140","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2337\/dc21-1758","volume":"45","author":"S Gancheva","year":"2022","unstructured":"Gancheva, S. et al. Impaired hepatic mitochondrial capacity in nonalcoholic steatohepatitis associated with type 2 diabetes. Diabetes Care 45, 928\u2013937 (2022).","journal-title":"Diabetes Care"},{"key":"898_CR141","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1194\/jlr.M063412","volume":"57","author":"E Kakazu","year":"2016","unstructured":"Kakazu, E., Mauer, A. S., Yin, M. & Malhi, H. Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1\u03b1-dependent manner. J. Lipid Res. 57, 233\u2013245 (2016).","journal-title":"J. Lipid Res."},{"key":"898_CR142","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/10408363.2015.1023429","volume":"52","author":"SE Park","year":"2015","unstructured":"Park, S. E., Park, C. Y. & Sweeney, G. Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit. Rev. Clin. Lab. Sci. 52, 180\u2013190 (2015).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"898_CR143","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng, L., Lam, K. S. L. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat. Rev. Endocrinol. 16, 654\u2013667 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR144","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.molmet.2015.06.001","volume":"4","author":"JS Hansen","year":"2015","unstructured":"Hansen, J. S. et al. Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans. Mol. Metab. 4, 551\u2013560 (2015).","journal-title":"Mol. Metab."},{"key":"898_CR145","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","volume":"30","author":"JE Lewis","year":"2019","unstructured":"Lewis, J. E., Ebling, F. J. P., Samms, R. J. & Tsintzas, K. Going back to the biology of FGF21: new insights. Trends Endocrinol. Metab. 30, 491\u2013504 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"898_CR146","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.28523","volume":"64","author":"Q Gong","year":"2016","unstructured":"Gong, Q. et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology 64, 425\u2013438 (2016).","journal-title":"Hepatology"},{"key":"898_CR147","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","volume":"30","author":"D Struik","year":"2019","unstructured":"Struik, D., Dommerholt, M. B. & Jonker, J. W. Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. Curr. Opin. Lipidol. 30, 235\u2013243 (2019).","journal-title":"Curr. Opin. Lipidol."},{"key":"898_CR148","doi-asserted-by":"publisher","first-page":"155347","DOI":"10.1016\/j.metabol.2022.155347","volume":"137","author":"SC Larsson","year":"2022","unstructured":"Larsson, S. C. et al. Circulating lipoprotein(a) levels and health outcomes: phenome-wide Mendelian randomization and disease-trajectory analyses. Metabolism 137, 155347 (2022).","journal-title":"Metabolism"},{"key":"898_CR149","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1152\/ajpendo.00050.2022","volume":"323","author":"RJ Samms","year":"2022","unstructured":"Samms, R. J. et al. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 323, E123\u2013e132 (2022). This study highlights the stimulating effect of certain glucose-lowering treatments on FGF21 in humans with T2DM.","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"898_CR150","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","volume":"34","author":"H Tilg","year":"2022","unstructured":"Tilg, H., Adolph, T. E. & Trauner, M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 34, 1700\u20131718 (2022).","journal-title":"Cell Metab."},{"key":"898_CR151","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan, N., Schick, F., Birkenfeld, A. L., H\u00e4ring, H. U. & White, M. F. The role of hepatokines in NAFLD. Cell Metab. 35, 236\u2013252 (2023).","journal-title":"Cell Metab."},{"key":"898_CR152","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt, M. J., Miotto, P. M., De Nardo, W. & Montgomery, M. K. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr. Rev. 40, 1367\u20131393 (2019).","journal-title":"Endocr. Rev."},{"key":"898_CR153","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1007\/s00125-017-4385-1","volume":"60","author":"F Gerst","year":"2017","unstructured":"Gerst, F. et al. Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion. Diabetologia 60, 2240\u20132251 (2017).","journal-title":"Diabetologia"},{"key":"898_CR154","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/nm.2851","volume":"18","author":"D Pal","year":"2012","unstructured":"Pal, D. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18, 1279\u20131285 (2012).","journal-title":"Nat. Med."},{"key":"898_CR155","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.2337\/db17-1268","volume":"67","author":"J Kr\u00f6ger","year":"2018","unstructured":"Kr\u00f6ger, J. et al. Circulating fetuin-A and risk of type 2 diabetes: a Mendelian randomization analysis. Diabetes 67, 1200\u20131205 (2018).","journal-title":"Diabetes"},{"key":"898_CR156","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cmet.2015.09.023","volume":"22","author":"RC Meex","year":"2015","unstructured":"Meex, R. C. et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab. 22, 1078\u20131089 (2015).","journal-title":"Cell Metab."},{"key":"898_CR157","doi-asserted-by":"publisher","first-page":"E266","DOI":"10.1152\/ajpendo.00262.2017","volume":"314","author":"A Peter","year":"2018","unstructured":"Peter, A. et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am. J. Physiol. Endocrinol. Metab. 314, E266\u2013e273 (2018).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"898_CR158","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2018.03.023","volume":"108","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: association and path analyses. Cytokine 108, 145\u2013150 (2018).","journal-title":"Cytokine"},{"key":"898_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17000-w","volume":"12","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. Hepatokine fetuin B expression is regulated by leptin-STAT3 signalling and associated with leptin in obesity. Sci. Rep. 12, 12869 (2022).","journal-title":"Sci. Rep."},{"key":"898_CR160","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/ars.2020.8087","volume":"33","author":"T Takamura","year":"2020","unstructured":"Takamura, T. Hepatokine selenoprotein P-mediated reductive stress causes resistance to intracellular signal transduction. Antioxid. Redox Signal. 33, 517\u2013524 (2020).","journal-title":"Antioxid. Redox Signal."},{"key":"898_CR161","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/antiox11071263","volume":"11","author":"R Yu","year":"2022","unstructured":"Yu, R. et al. Associations between circulating SELENOP level and disorders of glucose and lipid metabolism: a meta-analysis. Antioxidants 11, 1263 (2022).","journal-title":"Antioxidants"},{"key":"898_CR162","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nm.4295","volume":"23","author":"H Misu","year":"2017","unstructured":"Misu, H. et al. Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle. Nat. Med. 23, 508\u2013516 (2017).","journal-title":"Nat. Med."},{"key":"898_CR163","first-page":"169","volume":"22","author":"M Roden","year":"1995","unstructured":"Roden, M. et al. Metabolic effect of sodium selenite: insulin-like inhibition of glucagon-stimulated glycogenolysis in the isolated perfused rat liver. Hepatology 22, 169\u2013174 (1995).","journal-title":"Hepatology"},{"key":"898_CR164","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00125-022-05790-7","volume":"66","author":"P Simons","year":"2023","unstructured":"Simons, P. et al. Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht study. Diabetologia 66, 213\u2013222 (2023).","journal-title":"Diabetologia"},{"key":"898_CR165","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.tem.2021.05.002","volume":"32","author":"P Simons","year":"2021","unstructured":"Simons, P., Valkenburg, O., Stehouwer, C. D. A. & Brouwers, M. Sex hormone-binding globulin: biomarker and hepatokine? Trends Endocrinol. Metab. 32, 544\u2013553 (2021).","journal-title":"Trends Endocrinol. Metab."},{"key":"898_CR166","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-023-06249-4","volume":"619","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature 619, 143\u2013150 (2023). This study proposes a brain\u2013adipose-tissue\u2013skeletal muscle crosstalk mediated by GDF15 as a possible new therapeutic opportunity for maintaining body weight loss.","journal-title":"Nature"},{"key":"898_CR167","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1210\/endrev\/bnab021","volume":"42","author":"SE Kahn","year":"2021","unstructured":"Kahn, S. E. et al. The \u03b2 cell in diabetes: integrating biomarkers with functional measures. Endocr. Rev. 42, 528\u2013583 (2021).","journal-title":"Endocr. Rev."},{"key":"898_CR168","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2337\/db19-0138","volume":"69","author":"GC Weir","year":"2020","unstructured":"Weir, G. C. Glucolipotoxicity, \u03b2-cells, and diabetes: the emperor has no clothes. Diabetes 69, 273\u2013278 (2020).","journal-title":"Diabetes"},{"key":"898_CR169","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.jmb.2019.09.016","volume":"432","author":"M Lytrivi","year":"2020","unstructured":"Lytrivi, M., Castell, A. L., Poitout, V. & Cnop, M. Recent insights into mechanisms of \u03b2-cell lipo- and glucolipotoxicity in type 2 diabetes. J. Mol. Biol. 432, 1514\u20131534 (2020).","journal-title":"J. Mol. Biol."},{"key":"898_CR170","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","volume":"71","author":"BM Everett","year":"2018","unstructured":"Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J. Am. Coll. Cardiol. 71, 2392\u20132401 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"898_CR171","doi-asserted-by":"publisher","first-page":"836344","DOI":"10.3389\/fendo.2022.836344","volume":"13","author":"A Langlois","year":"2022","unstructured":"Langlois, A., Dumond, A., Vion, J., Pinget, M. & Bouzakri, K. Crosstalk communications between islets cells and insulin target tissue: the hidden face of iceberg. Front. Endocrinol. 13, 836344 (2022).","journal-title":"Front. Endocrinol."},{"key":"898_CR172","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cytogfr.2022.04.002","volume":"66","author":"D Gao","year":"2022","unstructured":"Gao, D. et al. The roles of cell-cell and organ-organ crosstalk in the type 2 diabetes mellitus associated inflammatory microenvironment. Cytokine Growth Factor. Rev. 66, 15\u201325 (2022).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"898_CR173","first-page":"26","volume":"11","author":"CB MarElia","year":"2018","unstructured":"MarElia, C. B., Kuehl, M. N., Shemwell, T. A., Alman, A. C. & Burkhardt, B. R. Circulating PANDER concentration is associated with increased HbA1c and fasting blood glucose in type 2 diabetic subjects. J. Clin. Transl. Endocrinol. 11, 26\u201330 (2018).","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"898_CR174","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206797120","volume":"120","author":"HJ Taylor","year":"2023","unstructured":"Taylor, H. J. et al. Human pancreatic islet microRNAs implicated in diabetes and related traits by large-scale genetic analysis. Proc. Natl Acad. Sci. USA 120, e2206797120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"898_CR175","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00125-022-05809-z","volume":"66","author":"H Zhu","year":"2023","unstructured":"Zhu, H. & Leung, S. W. MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling. Diabetologia 66, 288\u2013299 (2023). This meta-analysis confirmed the association of 16 pancreatic islet miRNAs with T2DM.","journal-title":"Diabetologia"},{"key":"898_CR176","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000603","volume":"18","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. Pancreatic \u03b2 cell microRNA-26a alleviates type 2 diabetes by improving peripheral insulin sensitivity and preserving \u03b2 cell function. PLoS Biol. 18, e3000603 (2020). This study indicates that miRNA26a mediates a complex crosstalk between the endocrine pancreas and the liver and adipose tissue.","journal-title":"PLoS Biol."},{"key":"898_CR177","doi-asserted-by":"publisher","first-page":"154844","DOI":"10.1016\/j.metabol.2021.154844","volume":"123","author":"M Nawrot","year":"2021","unstructured":"Nawrot, M., Peschard, S., Lestavel, S. & Staels, B. Intestine-liver crosstalk in type 2 diabetes and non-alcoholic fatty liver disease. Metabolism 123, 154844 (2021).","journal-title":"Metabolism"},{"key":"898_CR178","doi-asserted-by":"publisher","first-page":"bqab065","DOI":"10.1210\/endocr\/bqab065","volume":"162","author":"JJ Holst","year":"2021","unstructured":"Holst, J. J., Gasbjerg, L. S. & Rosenkilde, M. M. The role of incretins on insulin function and glucose homeostasis. Endocrinology 162, bqab065 (2021).","journal-title":"Endocrinology"},{"key":"898_CR179","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2022","unstructured":"Hammoud, R. & Drucker, D. J. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat. Rev. Endocrinol. 19, 201\u2013216 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR180","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun, T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol. Metab. 18, 3\u201314 (2018).","journal-title":"Mol. Metab."},{"key":"898_CR181","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Pfeiffer, A. F. H. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes. Metab. 23, 5\u201329 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"898_CR182","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13130","volume":"22","author":"D Rosendo-Silva","year":"2021","unstructured":"Rosendo-Silva, D. & Matafome, P. Gut-adipose tissue crosstalk: a bridge to novel therapeutic targets in metabolic syndrome? Obes. Rev. 22, e13130 (2021).","journal-title":"Obes. Rev."},{"key":"898_CR183","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11914-022-00767-2","volume":"21","author":"H Maagensen","year":"2023","unstructured":"Maagensen, H., Helsted, M. M., Gasbjerg, L. S., Vilsb\u00f8ll, T. & Knop, F. K. The gut\u2013bone axis in diabetes. Curr. Osteoporos. Rep. 21, 21\u201331 (2023).","journal-title":"Curr. Osteoporos. Rep."},{"key":"898_CR184","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.molmed.2013.05.006","volume":"19","author":"G Musso","year":"2013","unstructured":"Musso, G., Paschetta, E., Gambino, R., Cassader, M. & Molinaro, F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol. Med. 19, 522\u2013535 (2013).","journal-title":"Trends Mol. Med."},{"key":"898_CR185","doi-asserted-by":"publisher","first-page":"eaaw4176","DOI":"10.1126\/sciadv.aaw4176","volume":"5","author":"YS Lee","year":"2019","unstructured":"Lee, Y. S., Riopel, M., Cabrales, P. & Bandyopadhyay, G. K. Hepatocyte-specific HIF-1\u03b1 ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. Sci. Adv. 5, eaaw4176 (2019).","journal-title":"Sci. Adv."},{"key":"898_CR186","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nature26138","volume":"555","author":"DS Ghorpade","year":"2018","unstructured":"Ghorpade, D. S. et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555, 673\u2013677 (2018).","journal-title":"Nature"},{"key":"898_CR187","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41574-022-00757-5","volume":"19","author":"DA Sandoval","year":"2023","unstructured":"Sandoval, D. A. & Patti, M. E. Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia. Nat. Rev. Endocrinol. 19, 164\u2013176 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR188","doi-asserted-by":"publisher","first-page":"1029890","DOI":"10.3389\/fmicb.2022.1029890","volume":"13","author":"J Ye","year":"2022","unstructured":"Ye, J. et al. Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: advanced research-based review. Front. Microbiol. 13, 1029890 (2022).","journal-title":"Front. Microbiol."},{"key":"898_CR189","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41588-019-0350-x","volume":"51","author":"S Sanna","year":"2019","unstructured":"Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat. Genet. 51, 600\u2013605 (2019).","journal-title":"Nat. Genet."},{"key":"898_CR190","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-019-1236-x","volume":"569","author":"W Zhou","year":"2019","unstructured":"Zhou, W. et al. Longitudinal multi-omics of host\u2013microbe dynamics in prediabetes. Nature 569, 663\u2013671 (2019).","journal-title":"Nature"},{"key":"898_CR191","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2337\/dc14-2690","volume":"38","author":"MC Simon","year":"2015","unstructured":"Simon, M. C. et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care 38, 1827\u20131834 (2015).","journal-title":"Diabetes Care"},{"key":"898_CR192","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/nu13020558","volume":"13","author":"A Kanazawa","year":"2021","unstructured":"Kanazawa, A. et al. Effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: a randomized controlled study. Nutrients 13, 558 (2021).","journal-title":"Nutrients"},{"key":"898_CR193","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s43856-022-00185-6","volume":"2","author":"NC Penney","year":"2022","unstructured":"Penney, N. C. et al. Multi-omic phenotyping reveals host\u2013microbe responses to bariatric surgery, glycaemic control and obesity. Commun. Med. 2, 127 (2022).","journal-title":"Commun. Med."},{"key":"898_CR194","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmet.2017.09.008","volume":"26","author":"RS Kootte","year":"2017","unstructured":"Kootte, R. S. et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 26, 611\u2013619.e6 (2017).","journal-title":"Cell Metab."},{"key":"898_CR195","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/gutjnl-2020-323617","volume":"71","author":"SC Ng","year":"2022","unstructured":"Ng, S. C. et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut 71, 716\u2013723 (2022).","journal-title":"Gut"},{"key":"898_CR196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124242","volume":"10","author":"D Ziegler","year":"2015","unstructured":"Ziegler, D. et al. Differential patterns and determinants of cardiac autonomic nerve dysfunction during endotoxemia and oral fat load in humans. PLoS ONE 10, e0124242 (2015).","journal-title":"PLoS ONE"},{"key":"898_CR197","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.metabol.2016.12.009","volume":"68","author":"JMG Gomes","year":"2017","unstructured":"Gomes, J. M. G., Costa, J. A. & Alfenas, R. C. G. Metabolic endotoxemia and diabetes mellitus: a systematic review. Metabolism 68, 133\u2013144 (2017).","journal-title":"Metabolism"},{"key":"898_CR198","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","volume":"71","author":"WM de Vos","year":"2022","unstructured":"de Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020\u20131032 (2022).","journal-title":"Gut"},{"key":"898_CR199","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/nu15020272","volume":"15","author":"KS May","year":"2023","unstructured":"May, K. S. & den Hartigh, L. J. Gut microbial-derived short chain fatty acids: impact on adipose tissue physiology. Nutrients 15, 272 (2023).","journal-title":"Nutrients"},{"key":"898_CR200","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature18309","volume":"534","author":"RJ Perry","year":"2016","unstructured":"Perry, R. J. et al. Acetate mediates a microbiome\u2013brain\u2013\u03b2-cell axis to promote metabolic syndrome. Nature 534, 213\u2013217 (2016).","journal-title":"Nature"},{"key":"898_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4611","volume":"5","author":"G Frost","year":"2014","unstructured":"Frost, G. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014).","journal-title":"Nat. Commun."},{"key":"898_CR202","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","volume":"3","author":"A Stirban","year":"2014","unstructured":"Stirban, A., Gawlowski, T. & Roden, M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol. Metab. 3, 94\u2013108 (2014).","journal-title":"Mol. Metab."},{"key":"898_CR203","doi-asserted-by":"publisher","first-page":"166044","DOI":"10.1016\/j.bbadis.2020.166044","volume":"1867","author":"I Tuleta","year":"2021","unstructured":"Tuleta, I. & Frangogiannis, N. G. Diabetic fibrosis. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166044 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"898_CR204","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc. Diabetol. 17, 83 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"898_CR205","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2021.07.001","volume":"33","author":"RH Eckel","year":"2021","unstructured":"Eckel, R. H., Bornfeldt, K. E. & Goldberg, I. J. Cardiovascular disease in diabetes, beyond glucose. Cell Metab. 33, 1519\u20131545 (2021).","journal-title":"Cell Metab."},{"key":"898_CR206","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.121.056805","volume":"146","author":"F Eichelmann","year":"2022","unstructured":"Eichelmann, F. et al. Deep lipidomics in human plasma: cardiometabolic disease risk and effect of dietary fat modulation. Circulation 146, 21\u201335 (2022).","journal-title":"Circulation"},{"key":"898_CR207","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-022-01494-9","volume":"21","author":"E Karagiannidis","year":"2022","unstructured":"Karagiannidis, E. et al. Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease. Cardiovasc. Diabetol. 21, 70 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"898_CR208","doi-asserted-by":"publisher","first-page":"569250","DOI":"10.3389\/fendo.2020.569250","volume":"11","author":"BC Field","year":"2020","unstructured":"Field, B. C., Gordillo, R. & Scherer, P. E. The role of ceramides in diabetes and cardiovascular disease regulation of ceramides by adipokines. Front. Endocrinol. 11, 569250 (2020).","journal-title":"Front. Endocrinol."},{"key":"898_CR209","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.metabol.2018.01.017","volume":"83","author":"I Lakhani","year":"2018","unstructured":"Lakhani, I. et al. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis. Metabolism 83, 11\u201317 (2018).","journal-title":"Metabolism"},{"key":"898_CR210","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2174\/0929867325666171205144627","volume":"25","author":"HS Chung","year":"2018","unstructured":"Chung, H. S. & Choi, K. M. Adipokines and myokines: a pivotal role in metabolic and cardiovascular disorders. Curr. Med. Chem. 25, 2401\u20132415 (2018).","journal-title":"Curr. Med. Chem."},{"key":"898_CR211","doi-asserted-by":"publisher","first-page":"101040","DOI":"10.1016\/j.molmet.2020.101040","volume":"40","author":"X Lin","year":"2020","unstructured":"Lin, X. et al. Roles of bone-derived hormones in type 2 diabetes and cardiovascular pathophysiology. Mol. Metab. 40, 101040 (2020).","journal-title":"Mol. Metab."},{"key":"898_CR212","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3632","volume":"39","author":"E Maddaloni","year":"2023","unstructured":"Maddaloni, E. et al. Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes. Diabetes Metab. Res. Rev. 39, e3632 (2023).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"898_CR213","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tips.2018.02.010","volume":"39","author":"X Palomer","year":"2018","unstructured":"Palomer, X., Pizarro-Delgado, J. & V\u00e1zquez-Carrera, M. Emerging actors in diabetic cardiomyopathy: heartbreaker biomarkers or therapeutic targets? Trends Pharmacol. Sci. 39, 452\u2013467 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"898_CR214","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00125-019-05017-2","volume":"63","author":"C Niersmann","year":"2020","unstructured":"Niersmann, C. et al. Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes. Diabetologia 63, 410\u2013418 (2020).","journal-title":"Diabetologia"},{"key":"898_CR215","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbrc.2012.07.110","volume":"425","author":"X Zhong","year":"2012","unstructured":"Zhong, X., Li, X., Liu, F., Tan, H. & Shang, D. Omentin inhibits TNF-\u03b1-induced expression of adhesion molecules in endothelial cells via ERK\/NF-\u03baB pathway. Biochem. Biophys. Res. Commun. 425, 401\u2013406 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"898_CR216","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124935","volume":"10","author":"E Hatziagelaki","year":"2015","unstructured":"Hatziagelaki, E. et al. Serum chemerin concentrations associate with beta-cell function, but not with insulin resistance in individuals with non-alcoholic fatty liver disease (NAFLD). PLoS ONE 10, e0124935 (2015).","journal-title":"PLoS ONE"},{"key":"898_CR217","doi-asserted-by":"publisher","first-page":"e2572","DOI":"10.1210\/clinem\/dgac048","volume":"107","author":"D Chen","year":"2022","unstructured":"Chen, D. et al. Causal associations between circulating adipokines and cardiovascular disease: a Mendelian randomization study. J. Clin. Endocrinol. Metab. 107, e2572\u2013e2580 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"898_CR218","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12933-022-01616-3","volume":"21","author":"J Sabbatinelli","year":"2022","unstructured":"Sabbatinelli, J. et al. Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study. Cardiovasc. Diabetol. 21, 180 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"898_CR219","doi-asserted-by":"publisher","first-page":"eaay6191","DOI":"10.1126\/sciadv.aay6191","volume":"6","author":"XY Zhao","year":"2020","unstructured":"Zhao, X. Y. et al. The obesity-induced adipokine sST2 exacerbates adipose Treg and ILC2 depletion and promotes insulin resistance. Sci. Adv. 6, eaay6191 (2020).","journal-title":"Sci. Adv."},{"key":"898_CR220","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12933-021-01245-2","volume":"20","author":"D Jakubik","year":"2021","unstructured":"Jakubik, D. et al. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. Cardiovasc. Diabetol. 20, 55 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"898_CR221","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","volume":"1","author":"MC Thomas","year":"2015","unstructured":"Thomas, M. C. et al. Diabetic kidney disease. Nat. Rev. Dis. Prim. 1, 15018 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"898_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33507-7","volume":"8","author":"C Barrios","year":"2018","unstructured":"Barrios, C. et al. Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations. Sci. Rep. 8, 15249 (2018).","journal-title":"Sci. Rep."},{"key":"898_CR223","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.kint.2019.07.025","volume":"96","author":"M Kammer","year":"2019","unstructured":"Kammer, M. et al. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int. 96, 1381\u20131388 (2019).","journal-title":"Kidney Int."},{"key":"898_CR224","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrneph.2017.157","volume":"14","author":"Q Zhu","year":"2018","unstructured":"Zhu, Q. & Scherer, P. E. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat. Rev. Nephrol. 14, 105\u2013120 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"898_CR225","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrneph.2017.16","volume":"13","author":"G Targher","year":"2017","unstructured":"Targher, G. & Byrne, C. D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat. Rev. Nephrol. 13, 297\u2013310 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"898_CR226","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.freeradbiomed.2020.10.005","volume":"161","author":"K Zitouni","year":"2020","unstructured":"Zitouni, K. et al. Derepression of glomerular filtration, renal blood flow and antioxidant defence in patients with type 2 diabetes at high-risk of cardiorenal disease. Free. Radic. Biol. Med. 161, 283\u2013289 (2020).","journal-title":"Free. Radic. Biol. Med."},{"key":"898_CR227","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.2147\/JIR.S334996","volume":"14","author":"J Deng","year":"2021","unstructured":"Deng, J., Liu, Y., Liu, Y., Li, W. & Nie, X. The multiple roles of fibroblast growth factor in diabetic nephropathy. J. Inflamm. Res. 14, 5273\u20135290 (2021).","journal-title":"J. Inflamm. Res."},{"key":"898_CR228","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh, S. et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 90, 985\u2013996 (2016).","journal-title":"Kidney Int."},{"key":"898_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25299-8","volume":"12","author":"R Wu","year":"2022","unstructured":"Wu, R. et al. Identifying myoglobin as a mediator of diabetic kidney disease: a machine learning-based cross-sectional study. Sci. Rep. 12, 21411 (2022).","journal-title":"Sci. Rep."},{"key":"898_CR230","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-022-00608-6","volume":"18","author":"N Mahtal","year":"2022","unstructured":"Mahtal, N., Lenoir, O., Tinel, C., Anglicheau, D. & Tharaux, P.-L. MicroRNAs in kidney injury and disease. Nat. Rev. Nephrol. 18, 643\u2013662 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"898_CR231","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1007\/s00125-017-4264-9","volume":"60","author":"E Blond","year":"2017","unstructured":"Blond, E. et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia 60, 1218\u20131222 (2017).","journal-title":"Diabetologia"},{"key":"898_CR232","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801 (2019).","journal-title":"J. Hepatol."},{"key":"898_CR233","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41575-019-0239-2","volume":"17","author":"CD Byrne","year":"2020","unstructured":"Byrne, C. D. & Targher, G. What\u2019s new in NAFLD pathogenesis, biomarkers and treatment? Nat. Rev. Gastroenterol. Hepatol. 17, 70\u201371 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"898_CR234","doi-asserted-by":"publisher","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","volume":"111S","author":"B Dewidar","year":"2020","unstructured":"Dewidar, B., Kahl, S., Pafili, K. & Roden, M. Metabolic liver disease in diabetes \u2013 from mechanisms to clinical trials. Metabolism 111S, 154299 (2020).","journal-title":"Metabolism"},{"key":"898_CR235","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13695","volume":"52","author":"S Guerra","year":"2022","unstructured":"Guerra, S., Mocciaro, G. & Gastaldelli, A. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. Eur. J. Clin. Invest. 52, e13695 (2022).","journal-title":"Eur. J. Clin. Invest."},{"key":"898_CR236","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher, G., Corey, K. E., Byrne, C. D. & Roden, M. The complex link between NAFLD and type 2 diabetes mellitus \u2013 mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. 18, 599\u2013612 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"898_CR237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003149","volume":"17","author":"N Atabaki-Pasdar","year":"2020","unstructured":"Atabaki-Pasdar, N. et al. Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Med. 17, e1003149 (2020).","journal-title":"PLoS Med."},{"key":"898_CR238","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.jhepr.2022.100477","volume":"4","author":"AJ McGlinchey","year":"2022","unstructured":"McGlinchey, A. J. et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep. 4, 100477 (2022).","journal-title":"JHEP Rep."},{"key":"898_CR239","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001860","volume":"8","author":"M Apostolopoulou","year":"2020","unstructured":"Apostolopoulou, M. et al. Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans. BMJ Open. Diabetes Res. Care 8, e001860 (2020).","journal-title":"BMJ Open. Diabetes Res. Care"},{"key":"898_CR240","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1053\/j.gastro.2022.03.004","volume":"162","author":"TJ Velenosi","year":"2022","unstructured":"Velenosi, T. J. et al. Postprandial plasma lipidomics reveal specific alteration of hepatic-derived diacylglycerols in nonalcoholic fatty liver disease. Gastroenterology 162, 1990\u20132003 (2022).","journal-title":"Gastroenterology"},{"key":"898_CR241","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022775","volume":"6","author":"DL Gorden","year":"2011","unstructured":"Gorden, D. L. et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS ONE 6, e22775 (2011).","journal-title":"PLoS ONE"},{"key":"898_CR242","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"898_CR243","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3050","volume":"34","author":"S Cernea","year":"2018","unstructured":"Cernea, S., Roiban, A. L., Both, E. & Hutanu, A. Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 34, e3050 (2018).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"898_CR244","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","volume":"106","author":"TL Stanley","year":"2021","unstructured":"Stanley, T. L. et al. Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 106, e520\u2013e533 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"898_CR245","doi-asserted-by":"publisher","first-page":"106335","DOI":"10.1016\/j.cct.2021.106335","volume":"104","author":"MF Abdelmalek","year":"2021","unstructured":"Abdelmalek, M. F. et al. The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp. Clin. Trials 104, 106335 (2021).","journal-title":"Contemp. Clin. Trials"},{"key":"898_CR246","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.freeradbiomed.2020.08.005","volume":"160","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease. Free. Radic. Biol. Med. 160, 191\u2013198 (2020).","journal-title":"Free. Radic. Biol. Med."},{"key":"898_CR247","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26536-w","volume":"12","author":"C Wu","year":"2021","unstructured":"Wu, C. et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat. Commun. 12, 6486 (2021).","journal-title":"Nat. Commun."},{"key":"898_CR248","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex, R. C. R. & Watt, M. J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 13, 509\u2013520 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR249","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41576-020-0268-2","volume":"22","author":"K Suhre","year":"2021","unstructured":"Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. Nat. Rev. Genet. 22, 19\u201337 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"898_CR250","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1210\/jc.2015-4133","volume":"101","author":"B Knebel","year":"2016","unstructured":"Knebel, B. et al. Specific metabolic profiles and their relationship to insulin resistance in recent-onset type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 2130\u20132140 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"898_CR251","doi-asserted-by":"publisher","first-page":"382","DOI":"10.5604\/01.3001.0009.8593","volume":"16","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich, V., Sanguankeo, A., Riangwiwat, T. & Upala, S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann. Hepatol. 16, 382\u2013394 (2017).","journal-title":"Ann. Hepatol."},{"key":"898_CR252","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","volume":"6","author":"C Baumeier","year":"2017","unstructured":"Baumeier, C. et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol. Metab. 6, 1254\u20131263 (2017).","journal-title":"Mol. Metab."},{"key":"898_CR253","doi-asserted-by":"publisher","first-page":"4021623","DOI":"10.1155\/2019\/4021623","volume":"2019","author":"YJ Heo","year":"2019","unstructured":"Heo, Y. J. et al. Visfatin induces inflammation and insulin resistance via the NF-\u03baB and STAT3 signaling pathways in hepatocytes. J. Diabetes Res. 2019, 4021623 (2019).","journal-title":"J. Diabetes Res."},{"key":"898_CR254","doi-asserted-by":"publisher","first-page":"107885","DOI":"10.1016\/j.jdiacomp.2021.107885","volume":"35","author":"M Sagara","year":"2021","unstructured":"Sagara, M. et al. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. J. Diabetes Complications 35, 107885 (2021).","journal-title":"J. Diabetes Complications"},{"key":"898_CR255","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41574-019-0260-0","volume":"15","author":"C Ji","year":"2019","unstructured":"Ji, C. & Guo, X. The clinical potential of circulating microRNAs in obesity. Nat. Rev. Endocrinol. 15, 731\u2013743 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"898_CR256","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1210\/er.2018-00107","volume":"40","author":"GJ B\u00f6nhof","year":"2019","unstructured":"B\u00f6nhof, G. J. et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr. Rev. 40, 153\u2013192 (2019).","journal-title":"Endocr. Rev."},{"key":"898_CR257","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1210\/clinem\/dgab844","volume":"107","author":"K Guo","year":"2022","unstructured":"Guo, K. et al. Plasma metabolomics and lipidomics differentiate obese individuals by peripheral neuropathy status. J. Clin. Endocrinol. Metab. 107, 1091\u20131109 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"898_CR258","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/acn3.51639","volume":"9","author":"F Afshinnia","year":"2022","unstructured":"Afshinnia, F. et al. Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Ann. Clin. Transl. Neurol. 9, 1392\u20131404 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"898_CR259","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00125-020-05310-5","volume":"64","author":"D Ziegler","year":"2021","unstructured":"Ziegler, D. et al. Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. Diabetologia 64, 458\u2013468 (2021).","journal-title":"Diabetologia"},{"key":"898_CR260","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.tem.2019.02.007","volume":"30","author":"C Herder","year":"2019","unstructured":"Herder, C., Roden, M. & Ziegler, D. Novel insights into sensorimotor and cardiovascular autonomic neuropathy from recent-onset diabetes and population-based cohorts. Trends Endocrinol. Metab. 30, 286\u2013298 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"898_CR261","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13206","volume":"50","author":"MZ Kocak","year":"2020","unstructured":"Kocak, M. Z. et al. Is neuregulin-4 a predictive marker of microvascular complications in type 2 diabetes mellitus? Eur. J. Clin. Invest. 50, e13206 (2020).","journal-title":"Eur. J. Clin. Invest."},{"key":"898_CR262","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCRESAHA.120.315898","volume":"126","author":"ZZ Chen","year":"2020","unstructured":"Chen, Z. Z. & Gerszten, R. E. Metabolomics and proteomics in type 2 diabetes. Circ. Res. 126, 1613\u20131627 (2020).","journal-title":"Circ. Res."},{"key":"898_CR263","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41591-022-01980-3","volume":"28","author":"T Buergel","year":"2022","unstructured":"Buergel, T. et al. Metabolomic profiles predict individual multidisease outcomes. Nat. Med. 28, 2309\u20132320 (2022).","journal-title":"Nat. Med."},{"key":"898_CR264","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41591-022-02055-z","volume":"28","author":"J Carrasco-Zanini","year":"2022","unstructured":"Carrasco-Zanini, J. et al. Proteomic signatures for identification of impaired glucose tolerance. Nat. Med. 28, 2293\u20132300 (2022).","journal-title":"Nat. Med."},{"key":"898_CR265","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1016\/j.cell.2022.06.029","volume":"185","author":"RJ DeBerardinis","year":"2022","unstructured":"DeBerardinis, R. J. & Keshari, K. R. Metabolic analysis as a driver for discovery, diagnosis, and therapy. Cell 185, 2678\u20132689 (2022).","journal-title":"Cell"},{"key":"898_CR266","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s42255-021-00420-9","volume":"3","author":"L Wigger","year":"2021","unstructured":"Wigger, L. et al. Multi-omics profiling of living human pancreatic islet donors reveals heterogeneous beta cell trajectories towards type 2 diabetes. Nat. Metab. 3, 1017\u20131031 (2021).","journal-title":"Nat. Metab."},{"key":"898_CR267","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361\u2013369 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"898_CR268","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S2213-8587(19)30319-5","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia, O. P. et al. Diabetes clusters and risk of diabetes-associated diseases \u2013 authors\u2019 reply. Lancet Diabetes Endocrinol. 7, 828\u2013829 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"898_CR269","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002654","volume":"15","author":"MS Udler","year":"2018","unstructured":"Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 15, e1002654 (2018).","journal-title":"PLoS Med."},{"key":"898_CR270","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","volume":"27","author":"R Wagner","year":"2021","unstructured":"Wagner, R. et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat. Med. 27, 49\u201357 (2021). This analysis describes novel subtypes of prediabetes which are characterized by, among other variables, different degrees of insulinaemia and lipidaemia.","journal-title":"Nat. Med."},{"key":"898_CR271","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.2337\/db20-1281","volume":"70","author":"RC Slieker","year":"2021","unstructured":"Slieker, R. C. et al. Distinct molecular signatures of clinical clusters in people with type 2 diabetes: an IMI-RHAPSODY study. Diabetes 70, 2683\u20132693 (2021).","journal-title":"Diabetes"},{"key":"898_CR272","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.2337\/db21-0364","volume":"70","author":"JM Ratter-Rieck","year":"2021","unstructured":"Ratter-Rieck, J. M. et al. Leukocyte counts and T-cell frequencies differ between novel subgroups of diabetes and are associated with metabolic parameters and biomarkers of inflammation. Diabetes 70, 2652\u20132662 (2021).","journal-title":"Diabetes"},{"key":"898_CR273","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.2337\/db20-1054","volume":"70","author":"C Herder","year":"2021","unstructured":"Herder, C. et al. Differences in biomarkers of inflammation between novel subgroups of recent-onset diabetes. Diabetes 70, 1198\u20131208 (2021). This study provides evidence for specific differences in circulating proinflammatory biomarkers between the novel diabetes mellitus subtypes in a European population.","journal-title":"Diabetes"},{"key":"898_CR274","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34754-z","volume":"13","author":"SB Zaghlool","year":"2022","unstructured":"Zaghlool, S. B. et al. Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population. Nat. Commun. 13, 7121 (2022). This high-throughput proteomics and metabolomics study supports the concept of differences in multiomics signatures between novel diabetes mellitus subtypes in a non-European population.","journal-title":"Nat. Commun."},{"key":"898_CR275","doi-asserted-by":"publisher","first-page":"100958","DOI":"10.1016\/j.xcrm.2023.100958","volume":"4","author":"R Zheng","year":"2023","unstructured":"Zheng, R. et al. Data-driven subgroups of prediabetes and the associations with outcomes in Chinese adults. Cell Rep. Med. 4, 100958 (2023).","journal-title":"Cell Rep. Med."},{"key":"898_CR276","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00125-019-05019-0","volume":"63","author":"S Yuan","year":"2020","unstructured":"Yuan, S. & Larsson, S. C. Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study. Diabetologia 63, 116\u2013123 (2020).","journal-title":"Diabetologia"},{"key":"898_CR277","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002179","volume":"13","author":"LA Lotta","year":"2016","unstructured":"Lotta, L. A. et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a Mendelian randomisation analysis. PLoS Med. 13, e1002179 (2016).","journal-title":"PLoS Med."},{"key":"898_CR278","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85684-7","volume":"11","author":"E Porcu","year":"2021","unstructured":"Porcu, E. et al. Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes. Sci. Rep. 11, 6197 (2021).","journal-title":"Sci. Rep."},{"key":"898_CR279","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/nu12123890","volume":"12","author":"S J\u00e4ger","year":"2020","unstructured":"J\u00e4ger, S. et al. Mendelian randomization study on amino acid metabolism suggests tyrosine as causal trait for type 2 diabetes. Nutrients 12, 3890 (2020).","journal-title":"Nutrients"},{"key":"898_CR280","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2337\/db19-1070","volume":"69","author":"V Gudmundsdottir","year":"2020","unstructured":"Gudmundsdottir, V. et al. Circulating protein signatures and causal candidates for type 2 diabetes. Diabetes 69, 1843\u20131853 (2020).","journal-title":"Diabetes"},{"key":"898_CR281","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ije\/dyac036","volume":"51","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Genetically predicted sex hormone levels and health outcomes: phenome-wide Mendelian randomization investigation. Int. J. Epidemiol. 51, 1931\u20131942 (2022).","journal-title":"Int. J. Epidemiol."},{"key":"898_CR282","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10586-1","volume":"12","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Causal associations of circulating adiponectin with cardiometabolic diseases and osteoporotic fracture. Sci. Rep. 12, 6689 (2022).","journal-title":"Sci. Rep."},{"key":"898_CR283","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00125-020-05253-x","volume":"63","author":"S Yuan","year":"2020","unstructured":"Yuan, S. & Larsson, S. C. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. Diabetologia 63, 2359\u20132371 (2020).","journal-title":"Diabetologia"},{"key":"898_CR284","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/bcp.15191","volume":"88","author":"AJ Cupido","year":"2022","unstructured":"Cupido, A. J. et al. Dissecting the IL-6 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6R. Br. J. Clin. Pharmacol. 88, 2875\u20132884 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"898_CR285","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fgene.2019.00295","volume":"10","author":"H Zhuang","year":"2019","unstructured":"Zhuang, H., Han, J., Cheng, L. & Liu, S.-L. A positive causal influence of IL-18 levels on the risk of T2DM: a Mendelian randomization study. Front. Genet. 10, 295 (2019).","journal-title":"Front. Genet."},{"key":"898_CR286","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003451","volume":"17","author":"H Yun","year":"2020","unstructured":"Yun, H. et al. Associations among circulating sphingolipids, \u03b2-cell function, and risk of developing type 2 diabetes: a population-based cohort study in China. PLoS Med. 17, e1003451 (2020).","journal-title":"PLoS Med."},{"key":"898_CR287","first-page":"3439","volume":"106","author":"Y Sun","year":"2021","unstructured":"Sun, Y., Lu, Y. K., Gao, H. Y. & Yan, Y. X. Effect of metabolite levels on type 2 diabetes mellitus and glycemic traits: a Mendelian randomization study. J. Clin. Endocrinol. Metab. 106, 3439\u20133447 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"898_CR288","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2337\/db21-1046","volume":"71","author":"F Ghanbari","year":"2022","unstructured":"Ghanbari, F., Yazdanpanah, N., Yazdanpanah, M., Richards, J. B. & Manousaki, D. Connecting genomics and proteomics to identify protein biomarkers for adult and youth-onset type 2 diabetes: a two-sample Mendelian randomization study. Diabetes 71, 1324\u20131337 (2022).","journal-title":"Diabetes"},{"key":"898_CR289","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.2337\/dc18-2444","volume":"42","author":"M Pigeyre","year":"2019","unstructured":"Pigeyre, M. et al. Identification of novel causal blood biomarkers linking metabolically favorable adiposity with type 2 diabetes risk. Diabetes Care 42, 1800\u20131808 (2019).","journal-title":"Diabetes Care"},{"key":"898_CR290","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00125-021-05594-1","volume":"65","author":"I Drake","year":"2022","unstructured":"Drake, I. et al. The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease: evidence from cross-sectional, longitudinal and Mendelian randomisation analyses. Diabetologia 65, 128\u2013139 (2022).","journal-title":"Diabetologia"},{"key":"898_CR291","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02753-6","volume":"21","author":"D Zheng","year":"2023","unstructured":"Zheng, D. et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 21, 40 (2023).","journal-title":"BMC Med."},{"key":"898_CR292","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/cvr\/cvz030","volume":"115","author":"M Nikpay","year":"2019","unstructured":"Nikpay, M. et al. Genome-wide identification of circulating-miRNA expression quantitative trait loci reveals the role of several miRNAs in the regulation of cardiometabolic phenotypes. Cardiovasc. Res. 115, 1629\u20131645 (2019).","journal-title":"Cardiovasc. Res."},{"key":"898_CR293","doi-asserted-by":"publisher","first-page":"699455","DOI":"10.3389\/fgene.2021.699455","volume":"12","author":"Y Liang","year":"2021","unstructured":"Liang, Y., Luo, S., Schooling, C. M. & Au Yeung, S. L. Genetically predicted fibroblast growth factor 23 and major cardiovascular diseases, their risk factors, kidney function, and longevity: a two-sample Mendelian randomization study. Front. Genet. 12, 699455 (2021).","journal-title":"Front. Genet."},{"key":"898_CR294","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28496-1","volume":"13","author":"C Wittenbecher","year":"2022","unstructured":"Wittenbecher, C. et al. Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology. Nat. Commun. 13, 936 (2022).","journal-title":"Nat. Commun."},{"key":"898_CR295","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02566-z","volume":"20","author":"M Mora-Ortiz","year":"2022","unstructured":"Mora-Ortiz, M. et al. Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study. BMC Med. 20, 373 (2022).","journal-title":"BMC Med."},{"key":"898_CR296","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.coph.2022.102286","volume":"67","author":"AD MacCannell","year":"2022","unstructured":"MacCannell, A. D. & Roberts, L. D. Metabokines in the regulation of systemic energy metabolism. Curr. Opin. Pharmacol. 67, 102286 (2022).","journal-title":"Curr. Opin. Pharmacol."},{"key":"898_CR297","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","volume":"75","author":"X Xiong","year":"2019","unstructured":"Xiong, X. et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol. Cell 75, 644\u2013660.e5 (2019).","journal-title":"Mol. Cell"},{"key":"898_CR298","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2019.05.001","volume":"25","author":"F Gerst","year":"2019","unstructured":"Gerst, F. et al. What role do fat cells play in pancreatic tissue? Mol. Metab. 25, 1\u201310 (2019).","journal-title":"Mol. Metab."},{"key":"898_CR299","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cyto.2016.06.028","volume":"86","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. Adiponectin, TNF-\u03b1 and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine 86, 100\u2013109 (2016).","journal-title":"Cytokine"},{"key":"898_CR300","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00125-022-05801-7","volume":"66","author":"BT Steffen","year":"2023","unstructured":"Steffen, B. T. et al. Proteomic analysis of diabetes genetic risk scores identifies complement C2 and neuropilin-2 as predictors of type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetologia 66, 105\u2013115 (2023).","journal-title":"Diabetologia"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00898-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00898-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00898-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T09:03:30Z","timestamp":1702285410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00898-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":300,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1038\/s41574-023-00898-1","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"29 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R. has received personal fees for consulting from Eli Lilly, Novo Nordisk, Boehringer Ingelheim and Sanofi US, and has been supported for investigator-initiated trials by Boehringer Ingelheim, Novartis Pharma and Nutricia\/Danone. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}